HWA-131 (I) inhibited the carrageenan-induced paw edema in rats.I also demonstrated antierythema and antipyretic activities.I was effective in attenuating the active Arthus reaction in rats.I inhibited the adjuvant- and type II-collagen-induced arthritis in rats; these effects were accompanied by restoration of the depressed mitogen-induced lymphocyte response.In the chronic graft-vs.-host disease of mice (a model of systemic lupus erythematosus), I inhibited proteinurea due to glomerulonephritis and the decrease in spleen and kidney weight and other disease parameters.I also had antioxidative activity and inhibited the formation of LTB₄ and 5-HETE formation in human polymorphonuclear leukocytes and PGE₂ formation in rabbit mucosa.I also inhibited human platelet aggregation.I did not display any ulcerogenic potential and was well tolerated.I appears appears to be an effective nonsteroidal antirheumatic agent.

1989-01-01·Drugs under experimental and clinical research

Substituted 3-phenyl-7H-thiazolo(3,2-b)(1,2,4)triazin-7-ones as antiinflammatory agents with immunomodulating properties.

Article

作者: Kerékjártó, B ; Schleyerbach, R ; Gebert, U ; Weithmann, K U ; Bartlett, R R ; Thorwart, W

After structure-activity relationship studies (SAR) on a novel class of substituted thiazolo(3,2-b)(1,2,4)triazin-7-ones, HWA-131 (3-(3,5-di-tert.butyl-4-hydroxyphenyl)-7H-thiazolo(3,2-b)(1,2,4)triaz in-7-one) was selected for incremental pharmacological investigations. This compound was effective in not only preventing, but also curing established arthritic disorders of rats such as adjuvant and type II collagen arthritis as well as those of mice such as chronic graft-versus-host (CGVH) disease, a model for systemic lupus erythematosus (SLE). Further, this non-immunosuppressive drug effectively inhibited the carrageenan-induced paw oedema, attenuated the active Arthus reaction, and demonstrated antierythema as well as antipyretic activity. Part of the antiinflammatory effects of this new compound is most probably related to its antioxidative activity, as well as inhibition of lipoxygenase metabolites. HWA-131's good gastric tolerance may have to do with its limited ability to inhibit the production of cyclooxygenase metabolites. Based on our data, we are sure that HWA-131 will be an effective nonsteroidal antiinflammatory agent, with immunomodulating properties, to combat human autoimmune disorders.

100 项与 HWA-131 相关的药物交易

登录后查看更多信息